Alchemia/Dr Reddy's eye improved returns from fondaparinux process tweaks
This article was originally published in Scrip
Both Alchemia and commercial partner Dr Reddy's Laboratories are so far remaining mum on what impact their improved production process for fondaparinux may have on the end price or margins of their generic formulations of the injected anticoagulant.
You may also be interested in...
Merck/Eisai face US speed bump for combo in first-line liver cancer after FDA decision and although their Phase III trial is already enrolled, completion is not due until 2022, giving time for new competitor to make its mark.
Also, deals involving Sumitomo Dainippon, Tolero, Boston Biomedical, Zai Lab, Turning Point, SciClone, EpicentRx, Yuhan, GI Innovation, Takeda, Carmine, HitGen, Morphic, CStone and Burning Rock.
US pharma giant joins Singapore alliance aiming to encourage regional startups and innovation, in multiple tech-related areas including digital health, through the provision of expertise and support.